Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 28:2022:9693746.
doi: 10.1155/2022/9693746. eCollection 2022.

Correlation between the Expression of VEGF and Ki67 and Lymph Node Metastasis in Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Dong Wei  1 , Yunchao Xin  2 , Yu Rong  1 , Yanbing Hao  1
Affiliations
Review

Correlation between the Expression of VEGF and Ki67 and Lymph Node Metastasis in Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Dong Wei et al. Evid Based Complement Alternat Med. .

Retraction in

Abstract

Background: Lymph node metastasis is the most common and important way of metastasis in NSCLC and is also the most important factor affecting lung cancer stage and prognosis. It is very important to analyze the relationship between the expression of vascular endothelial growth factor (VEGF) and Ki67 and lymph node metastasis (LNM) in non-small-cell lung cancer (NSCLC).

Methods: We searched the PubMed, EMBASE, and Cochrane Library and conducted meta-analyses using the R meta-package. Relative risk (RR) with a 95% confidence interval (95% CI) was the main indicator.

Results: Totally, 18 studies were considered eligible, with 4521 patients, including 1518 LNM-positive patients and 3033 LNM-negative patients. The incidence of LNM in Ki67-negative patients was lower than that in Ki67-positive patients (RR = 0.66, 95% CI: 0.44, 0.98). The incidence of LNM in VEGF-A-negative patients was lower than that in VEGF-A-positive patients (RR = 0.64, 95% CI: 0.49, 0.83). The incidence of LNM in VEGF-C negative patients was lower than that in VEGF-C positive patients (RR = 0.68, 95% CI: 0.53, 0.88). The incidence of LNM in VEGF-D negative and positive patients were of no significant differences (RR = 0.84, 95% CI: 0.61, 1.14).

Conclusion: The high expression of Ki67, VEGF-A, and VEGF-C significantly increases the risk of lymph node metastasis in NSCLC, while the VEGF-D expression has no correlation with lymph node metastasis. The expression levels of Ki67, VEGF-A, and VEGF-C show a good potential for lymph node metastasis prediction.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Literature screening flowchart.
Figure 2
Figure 2
Included literature quality evaluation chart.
Figure 3
Figure 3
Forest plot of the Ki67 expression level and incidence of LNM.
Figure 4
Figure 4
Forest plot of the VEGF-A expression level and incidence of LNM.
Figure 5
Figure 5
Forest plot of the VEGF-C expression level and incidence of LNM.
Figure 6
Figure 6
Forest plot of the VEGF-D expression level and incidence of LNM.
Figure 7
Figure 7
Funnel plot of literature publication bias.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wu F., Wang L., Zhou C. Lung cancer in China: current and prospect. Current Opinion in Oncology . 2021;33(1):40–46. doi: 10.1097/cco.0000000000000703. - DOI - PubMed
    1. Thai A. A., Solomon B. J., Sequist L. V., Gainor J. F., Heist R. S. Lung cancer. The Lancet . 2021;398(10299):535–554. doi: 10.1016/s0140-6736(21)00312-3. - DOI - PubMed
    1. Bade B. C., Dela Cruz C. S. Lung cancer 2020. Clinics in Chest Medicine . 2020;41(1):1–24. doi: 10.1016/j.ccm.2019.10.001. - DOI - PubMed
    1. Ruiz-Cordero R., Devine W. P. Targeted therapy and checkpoint immunotherapy in lung cancer. Surgical Pathology Clinics . 2020;13(1):17–33. doi: 10.1016/j.path.2019.11.002. - DOI - PubMed
    1. Toumazis I., Bastani M., Han S. S., Plevritis S. K. Risk-based lung cancer screening: a systematic review. Lung Cancer . 2020;147:154–186. doi: 10.1016/j.lungcan.2020.07.007. - DOI - PubMed

LinkOut - more resources